AC
MRNS

Ascend Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Ascend Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-253,214
Closed -$8.26M – 280
2017
Q4 		$8.26M Buy
+253,214
New +$6.82M 0.31% 89

Other funds holding MRNS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
TBC
Three Bays Capital Boston, Massachusetts $848M AUM 7.41% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ascend Capital's MRNS Position: Q1 2018 in Review

Ascend Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2018, closing a stake of 253,214 shares — an estimated $8.26M sold.

Ascend Capital first reported a position in MRNS in Q4 2017 and held it in 1 quarter. The position peaked at $8.26M in Q4 2017. 60 funds tracked by Wall St. Rank hold MRNS as of Q1 2018.

  • Ascend Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 253,214 Marinus Pharmaceuticals, Inc shares in Q1 2018, an estimated $8.26M.
  • Ascend Capital first reported a position in Marinus Pharmaceuticals, Inc in Q4 2017 and held it in 1 quarter.
  • Ascend Capital's Marinus Pharmaceuticals, Inc position peaked at $8.26M in Q4 2017.
  • 60 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.